J Endocrinol Invest 28:41–49 26. Saito M, Marumo K, Kida Y, Ushiku C, Kato S, Takao-Kawabata R, Kuroda T (2011) Changes in the Selleckchem CB-839 contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1–34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys. Osteoporos

Int 22:2373–2383PubMedCrossRef 27. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH (2006) Change in lumbar find more spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21:1785–1790PubMedCrossRef 28. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10PubMedCrossRef 29. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289PubMedCrossRef 30. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD (2004) Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral

density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255–261PubMedCrossRef 31. Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, Selleckchem SHP099 Bianchi G, Bolognese MA, Christiansen C, Eastell R, Grauer A, Hawkins F, Kendler DL, Oliveri B, McClung MR, Reid IR, Siris ES, Zanchetta J, Zerbini CA, Libanati C, Cummings SR, FREEDOM Trial (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.

J Bone Miner Res 27:687–693 32. Jacques RM, Boonen S, PIK-5 Cosman F, Reid IR, Bauer DC, Black DM, Eastell R (2012) Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 27:1627–1634PubMedCrossRef”
“Addendum to: Osteoporos Int DOI 10.1007/s00198-013-2549-5 The author is pleased to supply the acknowledgements, inadvertently omitted from this article: Acknowledgements This work was funded by the National Health Research Institute (NHRI-EX101-9805PI) and the National Science Council (NSC100-2314-B-038-025), Taiwan, ROC.”
“Introduction Strontium ranelate has been in clinical use since 2004 for the management of postmenopausal osteoporosis, for which it reduces the risk of vertebral and nonvertebral fracture [1, 2].